Fundraising FoxAvicenna Biosciences
Durham, US · Founded 2020 · Delaware corporation · 1 known investors
Find your way into Avicenna Biosciences
Sign up to see every warm intro you have to Avicenna Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Avicenna Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
Founders & leadership
PB
Pieter BurgerExecutivePieter Burger is Co-founder and VP of Informatics at Avicenna Biosciences, where he applies computational methods—including molecular modeling, free energy calculations, molecular dynamics, and machine learning—to drug discovery and optimization. His research focuses on understanding how data quality and representation influence the reliability of computational predictions in medicinal chemistry.
TK
Thomas KaiserExecutiveThomas Kaiser trained in biochemistry, mathematics, organic chemistry, medicinal chemistry, artificial intelligence, and clinical medicine. He is an executive officer and director at Avicenna Biosciences, a biotechnology company developing therapeutics.
Board
CM
JH
DL
Dennis LangerBoard director
Investors · 1
DCVC BioreportedPalo Alto
How we know: board seat on SEC Form D · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$17.6M disclosed across 5 rounds · 2020–2024
▶$70.7KraisedOct 2025 · 1 investors · BiotechnologyRule 506(b)
▶$70.7KraisedOct 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pieter BurgerExecutive Officer, Director
- John HamerDirector
- Dennis LangerDirector
- Thomas KaiserExecutive Officer, Director
- Christopher MeldrumExecutive Officer, Director
- Offering amount
- $70.7K
- Amount sold
- $70.7K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedJul 2024 · 1 investors · BiotechnologyRule 506(b)
▶$6MraisedJul 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pieter BurgerExecutive Officer, Director
- Christopher MeldrumExecutive Officer, Director
- Thomas KaiserExecutive Officer, Director
- Dennis LangerDirector
- John HamerDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$6MraisedFeb 2024 · 1 investors · BiotechnologyRule 506(b)
▶$6MraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John HamerDirector
- Christopher MeldrumExecutive Officer, Director
- Thomas KaiserExecutive Officer, Director
- Pieter BurgerExecutive Officer, Director
- Dennis LangerDirector
- Offering amount
- $10M
- Amount sold
- $6M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3MraisedDec 2022 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedDec 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dennis LangerDirector
- John HamerDirector
- Pieter BurgerDirector
- Thomas KaiserExecutive Officer, Director
- Christopher MeldrumExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $3M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2.5MraisedSep 2020 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedSep 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pieter BurgerDirector
- Christopher MeldrumExecutive Officer, Director
- Thomas KaiserDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
GlobaldataGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Companies working in the same space as Avicenna Biosciences.
In the news
Frequently asked questions
- What does Avicenna Biosciences do?
- BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
- Who are Avicenna Biosciences's investors?
- Avicenna Biosciences's investors include DCVC Bio.
- How much funding has Avicenna Biosciences raised?
- Avicenna Biosciences has disclosed $17.6M raised across 5 rounds.
- Where is Avicenna Biosciences headquartered?
- Avicenna Biosciences is headquartered in Durham, US.